Search Results

• • 26 

    Academic Journals

  • Sort by: sorttype.publication.date.desc Newest sorttype.publication.date.asc Oldest sorttype.relevance Relevance

• Biomarkers and heart failure events in patients with atrial fibrillation in the ARISTOTLE trial evaluated by a multi-state model.

  Authors:Julia Aulin, Ziad Hijazi, Johan Lindbäck, John H. Alexander, Bernard J. Gersh, Christopher B. Granger, et al.From:American Heart Journal (Vol. 251) Peer-Reviewed

  Sept. 2022436 words Article

   Abstract Only

• Dabigratan versus Warfarin in patients with atrial fibrillation

  Authors:Stuart J. Connolly, Michael D. Ezekowitz, Salim Yusuf, John Eikelboom, Jonas Oldgren, Amit Parekh, et al.From:The New England Journal of Medicine (Vol. 361, Issue 12) Peer-Reviewed

  Sept. 17, 200952 words Clinical report

   Citation Only

• Pathophysiologic mechanisms of persistent cardiac troponin I elevation in stabilized patients after an episode of acute coronary syndrome

  Authors:Kai M. Eggers, Bo Lagerqvist, Jonas Oldgren, Per Venge, Lars Wallentin, and Bertil LindahlFrom:American Heart Journal (Vol. 156, Issue 3) Peer-Reviewed

  Sept. 2008192 words Report

   Abstract Only

• Coronary angiography in out-of-hospital cardiac arrest without ST elevation on ECG--Short- and long-term survival

  Authors:Ludvig Elfwen, Rickard Lagedal, Stefan James, Martin Jonsson, Ulf Jensen, Mattias Ringh, et al.From:American Heart Journal (Vol. 200) Peer-Reviewed

  June 2018441 words Report

   Abstract Only

• Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale; From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators.

  Authors:Anthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, Stuart J Connolly, John Eikelboom, Manesh R Patel, et al.From:American Heart Journal (Vol. 233) Peer-Reviewed

  Mar. 2021445 words Report

   Abstract Only

• Comparison of Dabigatran Plus a P2Y.sub.12 Inhibitor With Warfarin-Based Triple Therapy Across Body Mass Index in RE-DUAL PCI.

  Authors:Raffaele De Caterina, Antonio Procopio, José-Luis Lopez Sendon, Dimitar Raev, Shamir R. Mehta, Grzegorz Opolski, et al.From:American Journal of Medicine (Vol. 133, Issue 11) Peer-Reviewed

  Nov. 20201,257 words Report

   Abstract Only

• Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the [CHADS.sub.2] score: a subgroup analysis of the RE-LY trial

  Authors:Jonas Oldgren, Marco Alings, Harald Darius, Diener Hans-Christoph, John Eikelboom, Michael D. Ezekowitz, et al.From:Annals of Internal Medicine (Vol. 155, Issue 10) Peer-Reviewed

  Nov. 15, 2011354 words Author abstract, Cli...

   Abstract Only

• An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease

  Authors:Stefan K. James, Jonas Oldgren, Johan Lindback, Nina Johnston, Agneta Siegbahn, and Lars WallentinFrom:American Heart Journal (Vol. 149, Issue 4) Peer-Reviewed

  Apr. 2005 Article

   Citation Only

• Xa inhibition and coagulation activity -- the influence of prolonged dalteparin treatment and gender in patients with acute coronary syndrome and healthy individuals

  Authors:Jonas Oldgren, Nina Johnston, and Agneta SiegbahnFrom:American Heart Journal (Vol. 155, Issue 3) Peer-Reviewed

  Mar. 200899 words Author abstract, Rep...

   Abstract Only

• Diagnostic value of serial measurement of cardiac markers in patients with chest pain: limited value of adding myoglobin to troponin I for exclusion of myocardial infarction

  Authors:Kai Marten Eggers, Jonas Oldgren, Anna Nordenskjold, and Bertil LindahlFrom:American Heart Journal (Vol. 148, Issue 4) Peer-Reviewed

  Oct. 2004 Article

   Citation Only

• Application of Biomarkers for Risk Stratification in Patients with Atrial Fibrillation

  Authors:Ziad Hijazi, Jonas Oldgren, Agneta Siegbahn, and Lars WallentinFrom:Clinical Chemistry (Vol. 63, Issue 1) Peer-Reviewed

  Jan. 201710,150 words Report 1630L

   Citation Only

• The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study

  Authors:Ziad Hijazi, Jonas Oldgren, Joh LindbAaAaAeAnck, John H Alexander, Stuart J Connolly, John W Eikelboom, et al.From:The Lancet (Vol. 387, Issue 10035) Peer-Reviewed

  June 4, 2016558 words Article

   Abstract Only

• Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

  Authors:Jonathan P Piccini, Valeria Caso, Stuart J Connolly, Keith A A Fox, Jonas Oldgren, W Schuyler Jones, et al.From:The Lancet (Vol. 399, Issue 10333) Peer-Reviewed

  Apr. 9, 20221,499 words Clinical report

   Abstract Only

• Importance of persistent elevation of cardiac biomarkers in atrial fibrillation: a RE-LY substudy

  Authors:Ziad Hijazi, Jonas Oldgren, Ulrika Andersson, Stuart J. Connolly, Michael D. Ezekowitz, Stefan H. Hohnloser, et al.From:Heart (Vol. 100, Issue 15) Peer-Reviewed

  Aug. 1, 2014 Report

   Citation Only

• All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome

  Authors:Gorav Batra, Bodil Svennblad, Claes Held, Tomas Jernberg, Per Johanson, Lars Wallentin, et al.From:Heart (Vol. 102, Issue 12) Peer-Reviewed

  June 15, 2016 Report

   Citation Only

• Combination of a new oral anticoagulant, aspirin and clopidogrel after acute coronary syndrome: new therapeutic standard?

  Authors:Andrea Rubboli, Jonas Oldgren, Francisco MarA!n, and Gregory LipFrom:Internal and Emergency Medicine (Vol. 8, Issue 8) Peer-Reviewed

  Dec. 2013352 words Report

   Abstract Only

• Association between the use of fondaparinux vs low-molecular-weight heparin and clinical outcomes in patients with non-ST-segment elevation myocardial infarction

  Authors:Karolina Szummer, Jonas Oldgren, Lars Lindhagen, Juan Jesus Carrero, Marie Evans, Jonas Spaak, et al.From:JAMA, The Journal of the American Medical Association (Vol. 313, Issue 7) Peer-Reviewed

  Feb. 17, 201548 words Report

   Citation Only

• Dabigatran etexilate and reduction in serum apolipoprotein B

  Authors:Philip Joseph, Guillaume Pare, Lars Wallentin, Stuart Connolly, Salim Yusuf, Jia Wang, et al.From:Heart (Vol. 102, Issue 1) Peer-Reviewed

  Jan. 1, 2016 Report

   Citation Only

• Risk of mortality and stroke after atrial fibrillation - Authors' reply

  Authors:Jeff S. Healey and Jonas OldgrenFrom:The Lancet (Vol. 389, Issue 10072) Peer-Reviewed

  Mar. 4, 201738 words Article

   Abstract Only

• Effects of dabigatran according to age in atrial fibrillation

  Authors:Mandy N Lauw, John W Eikelboom, Salim Yusuf, Michael Ezekowitz, Jonas Oldgren, Juliet Nakamya, et al.From:Heart (Vol. 103, Issue 13) Peer-Reviewed

  July 1, 2017 Article

   Citation Only